doi: 10.1021/jf302791k
Disclosures: Alex Chang: Nothing to Disclose, Ethan Berman: Nothing to Disclose, Maham Ghani: Nothing to Disclose, Alexa Giammarino: Nothing to Disclose, Nishi Joshi: Nothing to Disclose, Nazia Qazi: Nothing to Disclose, Jennifer Onwochei: Nothing to Disclose, James Park: Nothing to Disclose, Nabil Dagher: Nothing to Disclose, Sanjaya Satapathy: Gilead Sciences: Grant/Research Support, Durect Pharma: Grant/Research Support, Fibronostics: Grant/Research Support, Novartis: Grant/Research Support, Zydus Pharma: Grant/Research Support, Boehringer Ingelheim: Grant/Research Support, Intercept Pharma: Grant/Research Support 1556 TRENDS IN POST-DISCHARGE PHARMACOLOGICAL ALCOHOL CESSATION THERAPY AND PSYCHIATRIC REFERRALS FOR HOSPITALIZED PATIENTS WITH ALCOHOL-ASSOCIATED LIVER DISEASE (ALD) BETWEEN 2014 TO 2023: A NATIONWIDE STUDY Emily Shu-Yen Chan 1 Yee Hui Yeo 2 Sikai Qiu 3 Hyunseok Kim 2 Peng-Sheng Ting 4 , 1 Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, 2 Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, LA, 3 Department of clinical medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 4 Tulane University School of Medicine Background: Alcohol- associated liver disease (ALD) is associated with high rates of alcohol relapse and unfortunately many patients do not follow up after discharge for alcohol cessation therapy
Parker JL et al., Molecular basis for redox control by the human cystine/glutamate antiporter system xc
Because its mostly included in combination supplements for brain support supplements that contain Huperzine A do not always make sense as a standalone motility support
